Phase 1–2 clinical trial: Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia.

Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Rilzabrutinib for blood disorder shows promise in phase 1–2 clinical trial – Massachusetts General Hospital

Commentary on Twitter

Rilzabrutinib had rapid and durable clinical activity in adults with immune thrombocytopenia, with low-level toxic effects. https://t.co/boWT4LpQkk pic.twitter.com/ZpNXHYL2Gv

— NEJM (@NEJM) April 18, 2022